Chronic kidney disease stage 5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The primary endpoint was renal replacement therapy (RRT) initiation.Half of the patients progressed to end stage renal disease (ESRD) during follow-up; they had lower eGFR, increased proteinuria, hematuria and serum cholesterol.
|
31277183 |
2019 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Kidney injury was determined using the lowest postoperative GFR within 7 days of surgery and standard Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease (RIFLE) classification criteria.
|
31272751 |
2019 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 70 years-old man with a dilated ischemic cardiomyopathy, triple coronary artery bypass grafting (CABG) in 1990 and chronic renal failure (baseline GFR: 45 ml/min/1.73 m<sup>2</sup>) underwent a coronary angiography for a Non-ST segment elevation myocardial infarction (NSTEMI).
|
29921223 |
2018 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the Ramipril Efficacy in Nephropathy study, ramipril decreased the rate of GFR decline (deltaGFR) and progression to end-stage renal disease (ESRD) in 352 patients with proteinuric chronic nephropathies.
|
10616844 |
2000 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined the incidence of diabetes in kidney donors, and compared GFR change over time in diabetic to nondiabetic donors, in addition to the effect of diabetes mellitus (DM) on the development of proteinuria, hypertension, and end-stage renal disease (ESRD).
|
28681494 |
2017 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariable analysis, ECF was significantly associated with the risk of ESKD (hazard ratio per 1L/1.73m<sup>2</sup> increase: 1.14; 95% confidence interval [1.07; 1.21]) and with a faster GFR decline (adjusted mean difference in mGFR slope per 1L/1.73m<sup>2</sup> increase -0.14 [-0.23; -0.05] mL/min/year).
|
31477263 |
2019 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though existing therapeutic options are effective in decreasing albuminuria, drugs targeting the preservation of GFR and prevention of ESRD may provide better strategy for the treatment.
|
30372836 |
2018 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altogether, we studied 189 patients with chronic kidney disease (CKD), comprising 149 patients with CKD stage 5 (glomerular filtration rate [GFR] < 15 mL/min; mean, 7 +/- 2 mL/min [<0.25 mL/s; mean, 0.12 +/- 0.03 mL/s]; 61% men; mean age, 54 +/- 12 years) and 40 patients with CKD stages 3 to 4 (GFR, 15 to 60 mL/min; mean, 33 +/- 21 mL/min [0.25 to 1.00 mL/s; mean, 0.55 +/- 0.35 mL/s]; 72% men; age, 59 +/- 15 years).
|
17261426 |
2007 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
For a doubling in hsTnT levels, and after adjustment for well-known risk factors, including NT-proBNP and hsCRP, the hazard ratio for ESRD at 1.26 was not significant in the diabetic nephropathy group, but there was a significant association with GFR decline after adjustment during follow-up (2.9 ml/min/1.73 m<sup>2</sup> annual decline per doubling in hsTnT).
|
28712855 |
2017 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Ala-allele is associated with enhanced decline in GFR and predicts ESRD and all-cause mortality in patients with nephropathy.
|
18467141 |
2008 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Family history of ESRD is common in older Americans and the increased risk of ESRD associated with a family history reflects lower GFR, higher albuminuria, and comorbid conditions.
|
22078058 |
2012 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the examination, 27 patients (18.6%) had a ≥50% decrease in GFR, of whom 4 (2.8%) had developed end-stage renal disease (ESRD).
|
29106593 |
2017 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, changes in urinary albumin and in GFR have been recognized as risk factors for the development of end-stage kidney disease and mortality.
|
31577820 |
2019 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
LKDs had increased risk of ESRD if they were male (adjusted hazard ratio [aHR]: 1.75, 95% confidence interval [95%CI]: 1.33-2.31), had higher BMI (aHR: 1.34 per 5 kg/m<sup>2</sup> , 95%CI: 1.10-1.64) or lower estimated GFR (aHR: 0.89 per 10 mL/min, 95% CI: 0.80-0.99), were first-degree relatives of the recipient (parent: [aHR: 2.01, 95% CI: 1.26-3.21]; full sibling [aHR: 1.87, 95%CI: 1.23-2.84]; identical twin [aHR: 19.79, 95%CI: 7.65-51.24]), or lived in lower socioeconomic status neighborhoods at donation (aHR: 0.87 per $10k increase; 95%CI: 0.77-0.99).
|
29392849 |
2018 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found a significant relation between initial creatinine (Cr), GFR, and urine 24 hour protein with developing ESRD ( p = 0.002, 0.039, < 0.001, respectively).
|
28420065 |
2017 |